59 related articles for article (PubMed ID: 8228555)
1. Endogenous testosterone, fibrinolysis, and coronary heart disease risk in hyperlipidemic men.
Glueck CJ; Glueck HI; Stroop D; Speirs J; Hamer T; Tracy T
J Lab Clin Med; 1993 Oct; 122(4):412-20. PubMed ID: 8228555
[TBL] [Abstract][Full Text] [Related]
2. Impaired endogenous fibrinolysis status: a potential prognostic predictor in ischemic stroke.
Chen Y; Gue Y; McDowell G; Gorog DA; Lip GYH
Minerva Med; 2024 May; ():. PubMed ID: 38727704
[TBL] [Abstract][Full Text] [Related]
3. Connecting impaired fibrinolysis and dyslipidemia.
Rodriguez M; Zheng Z
Res Pract Thromb Haemost; 2024 Mar; 8(3):102394. PubMed ID: 38706781
[TBL] [Abstract][Full Text] [Related]
4. D-Dimer and Fibrinogen Values according to the Localization of Deep Venous Thrombosis.
Mlačo A; Mlačo N; Begić E; Mekić M; Džubur A
Int J Angiol; 2023 Dec; 32(4):243-247. PubMed ID: 37927846
[TBL] [Abstract][Full Text] [Related]
5. Plasma tissue-type plasminogen activator is associated with lipoprotein(a) and clinical outcomes in hospitalized patients with COVID-19.
Zhang Z; Dai W; Zhu W; Rodriguez M; Lund H; Xia Y; Chen Y; Rau M; Schneider EA; Graham MB; Jobe S; Wang D; Cui W; Wen R; Whiteheart SW; Wood JP; Silverstein R; Berger JS; Kreuziger LB; Barrett TJ; Zheng Z
Res Pract Thromb Haemost; 2023 Aug; 7(6):102164. PubMed ID: 37680312
[TBL] [Abstract][Full Text] [Related]
6. Intracellular tPA-PAI-1 interaction determines VLDL assembly in hepatocytes.
Dai W; Zhang H; Lund H; Zhang Z; Castleberry M; Rodriguez M; Kuriakose G; Gupta S; Lewandowska M; Powers HR; Valmiki S; Zhu J; Shapiro AD; Hussain MM; López JA; Sorci-Thomas MG; Silverstein RL; Ginsberg HN; Sahoo D; Tabas I; Zheng Z
Science; 2023 Sep; 381(6661):eadh5207. PubMed ID: 37651538
[TBL] [Abstract][Full Text] [Related]
7. Worse progression of COVID-19 in men: Is testosterone a key factor?
Giagulli VA; Guastamacchia E; Magrone T; Jirillo E; Lisco G; De Pergola G; Triggiani V
Andrology; 2021 Jan; 9(1):53-64. PubMed ID: 32524732
[TBL] [Abstract][Full Text] [Related]
8. Sex-related differences in the association between plasma fibrinogen and non-calcified or mixed coronary atherosclerotic plaques.
Li T; Wang F; Peng R; Pei S; Hou Z; Lu B; Cong X; Chen X
Biol Sex Differ; 2018 Dec; 9(1):51. PubMed ID: 30518417
[TBL] [Abstract][Full Text] [Related]
9. Androgen actions on endothelium functions and cardiovascular diseases.
Cai JJ; Wen J; Jiang WH; Lin J; Hong Y; Zhu YS
J Geriatr Cardiol; 2016 Feb; 13(2):183-96. PubMed ID: 27168746
[TBL] [Abstract][Full Text] [Related]
10. Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review.
Meng F; Zhu S; Zhao J; Vados L; Wang L; Zhao Y; Zhao D; Niu Y
BMC Cancer; 2016 Mar; 16():180. PubMed ID: 26940836
[TBL] [Abstract][Full Text] [Related]
11. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies.
Zhao J; Zhu S; Sun L; Meng F; Zhao L; Zhao Y; Tian H; Li P; Niu Y
PLoS One; 2014; 9(9):e107516. PubMed ID: 25264674
[TBL] [Abstract][Full Text] [Related]
12. The ratio of second to fourth digit length (2D:4D) and coronary artery disease in a Han Chinese population.
Wu XL; Yang DY; Chai WH; Jin ML; Zhou XC; Peng L; Zhao YS
Int J Med Sci; 2013; 10(11):1584-8. PubMed ID: 24046536
[TBL] [Abstract][Full Text] [Related]
13. Testosterone and cardiovascular disease in men.
Morris PD; Channer KS
Asian J Androl; 2012 May; 14(3):428-35. PubMed ID: 22522504
[TBL] [Abstract][Full Text] [Related]
14. Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non-metastatic prostate cancer.
Cherrier MM; Aubin S; Higano CS
Psychooncology; 2009 Mar; 18(3):237-47. PubMed ID: 18636420
[TBL] [Abstract][Full Text] [Related]
15. Blood coagulation and fibrinolysis in male patients with hypogonadotropic hypogonadism: plasma factor V and factor X activities increase in hypogonadotropic hypogonadism.
Erem C; Kocak M; Hacihasanoglu A; Yilmaz M
J Endocrinol Invest; 2008 Jun; 31(6):537-41. PubMed ID: 18591887
[TBL] [Abstract][Full Text] [Related]
16. Testosterone for the aging male; current evidence and recommended practice.
Stanworth RD; Jones TH
Clin Interv Aging; 2008; 3(1):25-44. PubMed ID: 18488876
[TBL] [Abstract][Full Text] [Related]
17. Androgen deficiency as a predictor of metabolic syndrome in aging men: an opportunity for intervention?
Kapoor D; Jones TH
Drugs Aging; 2008; 25(5):357-69. PubMed ID: 18447401
[TBL] [Abstract][Full Text] [Related]
18. Short term effects of GnRH agonists on plasma fibrinolytic balance in patients with advanced prostate cancer.
Agirbasli M; Baykan OA; Tekin A; Sengor F; Cincin AA; Demir M; Vaughan DE
J Thromb Thrombolysis; 2009 Feb; 27(2):172-4. PubMed ID: 18183354
[TBL] [Abstract][Full Text] [Related]
19. Plasma adiponectin concentration in relation to severity of coronary atherosclerosis and cardiovascular risk factors in middle-aged men.
Dunajska K; Milewicz A; Jedrzejuk D; Szymczak J; Kuliczkowski W; Salomon P; Bialy D; Poczatek K; Nowicki P
Endocrine; 2004 Dec; 25(3):215-21. PubMed ID: 15758248
[TBL] [Abstract][Full Text] [Related]
20. Sex steroids and heart rate variability in patients after myocardial infarction.
Wranicz JK; Rosiak M; Cygankiewicz I; Kula P; Kula K; Zareba W
Ann Noninvasive Electrocardiol; 2004 Apr; 9(2):156-61. PubMed ID: 15084213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
